Passage Bio, Inc. (PASG)
After hours:
| Previous Close | 0.5960 |
| Open | 0.6050 |
| Bid | 0.0000 x 0 |
| Ask | 0.0000 x 0 |
| Day's Range | 0.5600 - 0.6099 |
| 52 Week Range | 0.5400 - 1.7900 |
| Volume | |
| Avg. Volume | 282,860 |
| Market Cap | 35.794M |
| Beta (5Y Monthly) | 1.19 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -1.3500 |
| Earnings Date | Nov 11, 2024 - Nov 15, 2024 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 6.75 |
- GuruFocus.com
Orbimed Advisors LLC Adjusts Stake in Passage Bio Inc
On September 19, 2024, Orbimed Advisors LLC, a prominent investment firm, executed a significant transaction involving the shares of Passage Bio Inc (NASDAQ:PASG). Despite this reduction, Orbimed Advisors LLC maintains a substantial position in Passage Bio, holding 12.62% of the company's shares, which represents 0.11% of their total portfolio. Founded in 1989, Orbimed Advisors LLC has grown into a global leader in healthcare investment, managing approximately $15 billion across various funds.
GlobeNewswirePassage Bio to Present at Chardan’s 8th Annual Genetic Medicines Conference
PHILADELPHIA, Sept. 23, 2024 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (NASDAQ: PASG), a clinical stage genetic medicines company focused on improving the lives of patients with neurodegenerative diseases, today announced that Will Chou, M.D., president and chief executive officer, will present at Chardan’s 8th Annual Genetic Medicines Conference on Tuesday, October 1, 2024 at 8:30 a.m. ET. A live webcast of the event will be available on the Investors & Media section of Passage Bio’s website at inv
